MGMT and pancreatic neuroendocrine tumor: Complete lack of MGMT expression appeared to characterize patients with pancreatic NET (5/8 pancreatic NET and 0/13 carcinoid tumors) who benefit significantly from temozolomide in 21 available specimens 76.